CN100374456C - 用于选择性癌症治疗的特异性人抗体 - Google Patents

用于选择性癌症治疗的特异性人抗体 Download PDF

Info

Publication number
CN100374456C
CN100374456C CNB018228852A CN01822885A CN100374456C CN 100374456 C CN100374456 C CN 100374456C CN B018228852 A CNB018228852 A CN B018228852A CN 01822885 A CN01822885 A CN 01822885A CN 100374456 C CN100374456 C CN 100374456C
Authority
CN
China
Prior art keywords
cell
ser
scfv
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018228852A
Other languages
English (en)
Chinese (zh)
Other versions
CN1551886A (zh
Inventor
Y·哈盖
J·拉扎罗维茨
R·盖伊
O·利普施茨
E·桑顿
A·莱瓦农
D·普拉克辛
T·佩雷茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of CN1551886A publication Critical patent/CN1551886A/zh
Application granted granted Critical
Publication of CN100374456C publication Critical patent/CN100374456C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB018228852A 2000-12-29 2001-12-31 用于选择性癌症治疗的特异性人抗体 Expired - Fee Related CN100374456C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
CN1551886A CN1551886A (zh) 2004-12-01
CN100374456C true CN100374456C (zh) 2008-03-12

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228852A Expired - Fee Related CN100374456C (zh) 2000-12-29 2001-12-31 用于选择性癌症治疗的特异性人抗体

Country Status (15)

Country Link
EP (1) EP1353937A4 (fr)
JP (1) JP2004524023A (fr)
KR (1) KR20030091952A (fr)
CN (1) CN100374456C (fr)
AU (1) AU2002246737B2 (fr)
BR (1) BR0116763A (fr)
CA (1) CA2433227A1 (fr)
CZ (1) CZ20031983A3 (fr)
HU (1) HUP0400775A2 (fr)
IL (1) IL156690A0 (fr)
MX (1) MXPA03005944A (fr)
NZ (1) NZ527173A (fr)
PL (1) PL365758A1 (fr)
RU (1) RU2316564C2 (fr)
WO (1) WO2002059264A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (fr) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions et procedes pour traitement therapeutique
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
EP2444421A1 (fr) 2005-04-26 2012-04-25 Pfizer Inc. Anticorps de la P-Cadherine
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
KR102023289B1 (ko) * 2014-10-23 2019-09-19 싱 몰레큘러 메디신, 엘엘씨 세포내 항원에 대해 지향된 단일 도메인 항체
US20160176983A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
AU2016329542C1 (en) * 2015-10-01 2023-11-23 Fondazione Centro San Raffaele TCR and uses thereof
WO2017087789A1 (fr) * 2015-11-19 2017-05-26 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
KR102505681B1 (ko) * 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 Cd3 결합 항체
EP4244251A1 (fr) * 2020-11-13 2023-09-20 Prometheus Biosciences, Inc. Méthodes, systèmes et kits pour le traitement d'une maladie inflammatoire ciblant tl1a

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251532A (zh) * 1997-01-22 2000-04-26 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子方法和组合物
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
CN1251532A (zh) * 1997-01-22 2000-04-26 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子方法和组合物
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
NZ527173A (en) 2006-03-31
MXPA03005944A (es) 2005-04-29
BR0116763A (pt) 2004-03-09
CA2433227A1 (fr) 2002-08-01
JP2004524023A (ja) 2004-08-12
KR20030091952A (ko) 2003-12-03
RU2316564C2 (ru) 2008-02-10
IL156690A0 (en) 2004-01-04
CZ20031983A3 (cs) 2005-07-13
EP1353937A4 (fr) 2005-04-13
EP1353937A2 (fr) 2003-10-22
AU2002246737B2 (en) 2007-03-01
HUP0400775A2 (en) 2007-05-02
WO2002059264A3 (fr) 2003-03-06
PL365758A1 (en) 2005-01-10
RU2003123100A (ru) 2005-03-10
CN1551886A (zh) 2004-12-01
WO2002059264A2 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
CN100374456C (zh) 用于选择性癌症治疗的特异性人抗体
CN101044242B (zh) 肿瘤特异性抗体
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN101671393A (zh) 血管生成素-2的特异结合剂
KR20040044408A (ko) 항 trail-r 항체
CN101479296A (zh) Trail受体结合剂和其用途
WO2000020460A1 (fr) Production d'anticorps specifiques d'antigenes tumoraux humains
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN101389791A (zh) 融合蛋白文库的产生和筛选方法及其应用
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
JP2005503756A (ja) 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
JP2005503756A5 (fr)
EP1033406A1 (fr) Inducteur pour la production d'un anticorps specifique de l'antigene, vecteur d'expression contenant le gene requis a cette fin, et procede pour induire la production de l'anticorps specifique de l'antigene
WO2004003166A2 (fr) Anticorps et leurs applications
CN101300021A (zh) 抗体及其用途
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
US20040208877A1 (en) Antibodies and uses thereof
CN116496396B (zh) 抗cd70纳米抗体及其用途
JP2012515158A (ja) 癌の予防・治療剤
Nadal Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads
CN117843793A (zh) 抗间皮素抗体、抗原结合片段及其用途
FI106129B (fi) Menetelmät valmistaa muuntuneita CD44-pintaproteiineja ja näitä proteiineja vastaan vaikuttavia vasta-aineita

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee